Thursday, February 6, 2025
4.7 C
London
HomeFinTechPatrys: Receives $3.35m R&D tax incentive refund

Patrys: Receives $3.35m R&D tax incentive refund

Date:

BMO Integrates Embedded Finance into Business ERP Systems

Discover how BMO is transforming financial services for businesses...

Lunar Hires Nanna Bergmann to Lead BAAS Spinoff

Nanna Bergmann Appointed to Head Lunar’s New Banking-as-a-Service EntityHighlights:...

Patrys Receives $3.35m R&D tax incentive refund

  • Patrys (PAB) subsidiary Nucleus Therapeutics receives a $3.35 million research and development tax incentive refund from the Australian Federal Government
  • The funds are for R&D undertaken during the 2021/2022 financial year
  • The company CEO and Managing Director James Campbell says the company is “extremely grateful” for the support the government provides to the Australian biotech industry
  • This rebate, in combination with Pat rys’ existing cash balance, will enable the company to continue advancing its treatments for a range of cancers in the second half of 2023
  • The company  is down 3.13 per cent and trading at 3.1 cents at 2:32 pm AEDT

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories